QURE

QURE

QURE

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2025 Q2	Jul 27, 2025	Diamond Hill International	11.7%	16.1%	8604.T, AEM, BABA, BEI.TO, BYG.L, FNV, HDB, HIK.L, ICLR, ITSA4.SA, KRN.DE, QURE, S68.SI, SDZ, TSM, WISE.L, WMMVY	AI, Asia, Buybacks, China, international, Intrinsic Value, Japan, value	Chinese equities rallied on growing confidence that domestic producers are becoming less reliant on foreign suppliers in artificial intelligence. TSMC benefited from strong demand for advanced manufacturing tied to AI and high-performance computing. Alibaba is increasingly viewed as a leader in China's AI landscape.	KRN.DE WMMVY HDB TSM BABA QURE HAL IN	View
2025 Q1	Apr 24, 2025	Diamond Hill International	4.0%	4.0%	2875.T, 6501.T, 8058.T, ABEV, BABA, BAER.SW, BAP, BEI-UN.TO, BTI, BYG.L, GLEN.L, GSK, IMB.L, MRO.L, NWC.TO, QURE, SAF.PA, SPOT, TSM	aerospace, AI, Asia, Europe, infrastructure, international, real estate, value	Chinese AI innovation, particularly DeepSeek, demonstrated capability to rival US technologies at significantly lower costs, underscoring intensifying global AI competition. Alibaba benefited from market optimism around its AI initiatives and expanded capital investment to bolster AI capabilities.	6501.T BEI.UN.TO BYG.L MRO.L NWC.TO 2875.T IMB.L BTI QURE GLEN.L TSM SAF.PA SPOT BABA	View
2025 Q4	Feb 2, 2026	Warden Capital	0.0%	0.0%	ARE, MTN, PLD, PLTR, QURE	AI, Biotechnology, Commercial real estate, Defensive, Shorts, value	Manager believes AI capex is at unsustainable levels and won't generate economic returns unless true AGI emerges imminently. OpenAI's user growth appears to be stalling with weak Q4 traffic growth, while competitors like Gemini continue growing strongly. Model progress may be reaching diminishing returns as current state-of-the-art models are not universally better than previous versions. CRE markets show little major change from previous commentary. Apartments remain soft due to oversupply and weaker sunbelt demand, industrial has picked up slightly, office is weak outside NYC but improving in class A, retail continues doing well due to lack of new supply, and hospitality is softer than expected. Manager invested in uniQure, a biotech with potential groundbreaking gene therapy for Huntington's disease. Initial results showed disease progression slowing by 75% three years after treatment, but FDA rescinded agreement on external control group causing stock to crash. Manager believes therapy will ultimately get approved given strong efficacy data.	QURE PLTR ARE MTN	View
2024 Q4	Dec 31, 2024	Diamond Hill International	-7.5%	4.0%	005930.KS, 0700.HK, 7999.T, BOLSAA.MX, EXO.MI, GLEN.L, KRN.DE, PRX.AS, QURE, RACE, SPOT, STLA, TSM, UHR.SW	China, Europe, Gene Therapy, India, international, Japan, semiconductors, value	uniQure's Huntington's disease treatment program advanced with FDA accelerating the approval pathway for its gene therapy treatment. The company demonstrates leadership in innovative therapies and ability to navigate gene therapy development complexities. Future royalty streams and broader drug pipeline position it as an attractive long-term opportunity.	KRN.DE 7454.T PRX.AS EXO.MI GLEN.L 005930.KS TSM SPOT QURE	View
2025 Q3	Nov 8, 2025	Summers Value Fund	20.4%	4.9%	ADMA, CCSI, DERM, ELMD, INSP, LGND, LQDA, QURE, SPOK, SPRY, UFPT, ZIMV	Biotechnology, healthcare, innovation, M&A, Pharmaceuticals, Regulatory, small cap, value	The fund has increased portfolio exposure to biopharma stocks following years of underperformance, believing they are poised for outperformance. The manager is optimistic about the innovation cycle and recognizes that large-cap companies will pay sizeable premiums to acquire attractive pipelines with large sales opportunities.		View
2025 Q3	Oct 24, 2025	Diamond Hill International	6.5%	23.6%	8604.T, AEM, BABA, BEI.TO, BYG.L, FNV, HDB, HIK.L, ICLR, ITSA4.SA, KRN.DE, QURE, S68.SI, SDZ, TSM, WISE.L, WMMVY	AI, Buybacks, China, gold, international, Intrinsic Value, Japan, value	Chinese equities rallied on growing confidence that domestic producers are becoming less reliant on foreign suppliers in artificial intelligence. TSMC benefited from strong demand for advanced manufacturing tied to AI and high-performance computing. Alibaba is increasingly viewed as a leader in China's AI landscape with continued investment in AI and cloud.	HIK FRAN TSM	View
2025 Q3	Oct 21, 2025	Deep Sail Capital Partners	5.8%	18.1%	CLPT, HIMS, NURS.V, ONON, PNG.TO, QURE, VST.V, WSTL	Biotechnology, Bubble, defense, Gene Therapy, growth, small caps, Speculation, Telehealth	Hydreight Technologies represents a major position in the telehealth space, operating a vertically integrated mobile health platform combining SaaS technology with healthcare services. The company has experienced exceptional growth from $3 million in 2022 to over $100 million forecast in the next 12 months. VSDHOne platform enables consumer health brands to launch nationwide telehealth offerings in days, capitalizing on the trend following Hims & Hers' success.		View
2025 Q3	Oct 19, 2025	Minot Light Capital Partners	7.6%	12.5%	ARQ, CLPT, CURV, LGCY, LUCD, PAVM, QURE, REAL, SWAG	Beta-sliding, growth, healthcare, Micro-Cap, small caps, value	The fund is heavily positioned in out-of-favor healthcare stocks with strong business models, high growth potential, and substantial embedded optionality. ClearPoint Neuro provides hardware and consumables for precise drug delivery to brain and spine, particularly for cell and gene therapies. Lucid Diagnostics markets an FDA-approved DNA test for early detection of esophageal precancer with multi-billion dollar market opportunity pending Medicare reimbursement approval.	SWAG LUCD CURV ARQ CLPT REAL	View
2025 Q3	Oct 14, 2025	RTW Investments	-	17.5%	AKRO, PTCT, QURE, RNA, STOK, TARS, URGN, VSTM	Biotechnology, Commercial, Development, Gene Therapy, M&A, Oncology, Rare Diseases	Development stage M&A activity accelerated in September with three significant acquisitions announced over two weeks. Roche acquired MASH company 89Bio for $2.4 billion, Pfizer bought Metsera's obesity pipeline for $4.9 billion, and Genmab acquired Merus for $8 billion. Multinational pharmas have worked through manufacturing and tariff uncertainties and have more clarity on their budgets, leading to expectations of more development stage deals.		View
2025 Q4	Jan 28, 2026	Rodrigo Benedetti	0.0%	0.0%	ARKK, CLS, KITS.TO, MSFT, NBIS, ORCL, QQQ, QURE, REGN, SLNO, SPY, STRL, TEVA, TGEN, TSSI, TWST, VRT, XOP	AI, Biotechnology, commodities, Fintech, gold, healthcare, oil	Manager observes precious metals experiencing massive bubble-like moves with gold and silver going through blow-off tops. Believes there is no fundamental reason for this rally and compares moves to the 1970s when US abandoned gold standard. AI companies, particularly neoclouds, corrected 50% but are showing signs of life again. Manager previously shorted low quality AI names trading on high multiples but closed positions when momentum couldn't be fought. Oil equities have diverged from oil prices with E&P, OFS and Majors underperforming. Manager notes well-supplied market and Chinese demand reduction while they add to strategic reserves. Mixed results in biotech with FDA walking back QURE approval after mixed data causing roundtrip of profits. Healthcare sector performed well with TEVA and REGN benefiting from immunity to tariffs and AI disruption. Excited about Figure Technologies at crossroads of blockchain and electronic HELOC securitization. Company provides bridge for stablecoin yield investment and operates marketplace for on-chain loan investment with fraud-resistant electronic system.	EMO CN KITS CN	View
2025 Q4	Jan 15, 2026	Alger Small Cap Focus Fund	3.6%	6.9%	ABT, EXAS, GH, NBIS, NTRA, QURE, STVN	AI, Biotechnology, Diagnostics, growth, healthcare, small cap, technology	The market's biggest tailwind was continued investment tied to artificial intelligence, though increasingly accompanied by scrutiny around AI infrastructure bottlenecks, sources of financing, and whether the AI theme could deliver returns commensurate with capital deployed. U.S. business spending appears to be accelerating, driven by burgeoning demand for AI infrastructure. Multiple portfolio holdings focus on cancer diagnostics and treatment, including molecular diagnostics companies specializing in liquid biopsy tests, colorectal cancer screening, and molecular residual disease testing. The oncology testing market shows strong momentum with favorable reimbursement dynamics and higher test volumes. Cloud computing is growing and supporting innovation, with corporations digitizing their operations. The fund holds positions in AI-focused cloud infrastructure providers operating GPU compute capacity, benefiting from accelerating AI adoption as demand for high-quality GPU compute continues to outstrip available supply. Portfolio includes biotechnology companies developing gene therapies for rare diseases like Huntington's disease, an area with no approved disease-modifying treatments. The sector faces regulatory uncertainty but shows encouraging efficacy signals in clinical trials.	STVN QURE NBIS NTRA GH EXAS	View
2025 Q4	Jan 14, 2026	Apis Flagship Fund	10.0%	55.1%	012450.KS, 086280.KS, 103140.KS, AI, CELC, GTX, QURE	Asia, defense, global, healthcare, Memory, Mining, small caps, technology	Defense exposure continued from 2024 but evolved toward smaller companies with niche intellectual property. Korean defense holdings including Hyundai Rotem, Poongsan, and Hanwha Aerospace were among top contributors for the year, collectively adding over 11% to annual performance despite some Q4 weakness attributed to technical pause. New theme emerged in 2025 with exposure to memory within the semiconductor complex. Memory semiconductor companies were notable source of strength, contributing more than 5% to Q4 returns, led by Japan-based Kioxia Holdings which was highlighted in Q3 letter. Mining and mining equipment emerged as new theme in 2025. Represents bombed out cyclical exposure where valuations remain cheap and expectations modest, yet early signs of demand are emerging supported by fiscal stimulus programs. European building materials represents another area of bombed out cyclical exposure beyond mining where exposure was added. Valuations remain cheap and expectations modest with early signs of demand emerging supported by fiscal stimulus programs. Resolution to Ukraine war could further enhance long-term growth outlook.	AI QURE CELC	View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Apr 13, 2026	Fund Letters	Diamond Hill International	uniQure N.V.	Health Care	Biotechnology	Bull	NASDAQ	biotechnology, FDA, gene therapy, manufacturing, Netherlands, pipeline, Regulatory	View Pitch
Apr 13, 2026	Fund Letters	Diamond Hill International	uniQure N.V.	Health Care	Biotechnology	Bull	NASDAQ	AMT-130, biotechnology, Clinical trials, gene therapy, Huntington's Disease, Netherlands, Royalty Streams	View Pitch
Apr 13, 2026	Fund Letters	Diamond Hill International	uniQure N.V.	Health Care	Biotechnology	Bull	NASDAQ	biotechnology, drug pipeline, FDA approval, gene therapy, growth, Huntington's Disease, Netherlands, Royalty Streams	View Pitch
Feb 4, 2026	Fund Letters	Hawkins Entrekin	uniQure N.V.	Health Care	Biotechnology	Bull	NASDAQ	Biotech, clinical data, gene therapy, Optionality, Regulation	View Pitch
Jan 27, 2026	Fund Letters	Amy Zhang	uniQure N.V.	Health Care	Biotechnology	Bear	NASDAQ	FDA, Genetherapy, Neurology, Regulatory, Volatility	View Pitch
Jan 23, 2026	Twitter / X	@chaotropy	uniQure N.V.	Health Care	Gene Therapy	Bull	NASDAQ	Amt, Disease, FDA, Gene, gene therapy, Huntington, Therapy, UniQure	View Pitch
Jan 20, 2026	Fund Letters	Daniel Barker	UniQure N.V.	Health Care	Biotechnology	Bear	NASDAQ	Biotech, Clinicalrisk, Genetherapy, Volatility	View Pitch
Jan 8, 2026	Substack	Triples Investing	uniQure N.V.	Biotechnology	Gene Therapy	Bull	NASDAQ Stock Market	AMT-130, biotechnology, Clinical trials, disease progression, gene therapy, Global Market, Huntington's Disease, neurodegeneration, Regulatory Approval, UniQure	View Pitch
Nov 25, 2025	Substack	Triples Investing	UniQure	Health Care	Biotechnology	Bull		AMT-130, biotechnology, clinical trial data, FDA regulatory uncertainty, gene therapy, Huntington's Disease, investment opportunity, regulatory pathways, stock undervaluation, UniQure	View Pitch

BSD Shareholders of QURE

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: